01.04.2020 | Insight

#COVID19: HCPs use Twitter polls for advice and to get a ‘feel’ of the wider practice

By Laura McIntyre

#COVID19: HCPs use Twitter polls for advice and to get a ‘feel’ of the wider practice

Coronavirus has not only disrupted medical practice but brought a sense of uncertainty to it. As real-world data on the impact of the virus keeps emerging, HCPs use public social media to connect with one another seeking advice, assurance and to get a ‘feel’ of the wider practice.

HCPs such as UK cardiologist Mamas Mamas, are utilizing Twitter polls to understand if and how coronavirus might have changed their clinical procedures, encouraging others to share their posts, vote and comment.

US Coronary intervention doctor Sripal Bangalore, created a whole thread of polls for each stage of testing and diagnosis of a patient case.

Michael Griksaitis, in the UK, engaged his pediatric intensive care community around retesting children for coronavirus. Interestingly, in a similar poll from Sripal Bangalore the results were slightly different.

A UK Cardiologist, Vass Vassiliou, also turned to his peers for their opinion on polymerase chain reaction test sensitivity when detecting the virus and asked his colleagues to explain their reasoning by commenting on his post.

What are the real informational needs of your HCP customers? How can you add value and directly support them instead of just adding to the noise? Head onto our website, creation.co/COVID19, to find out more.

CREATION.co has been tracking the online HCP conversation relating to coronavirus since the start of the outbreak and is committed to supporting healthcare stakeholders globally.

View all articles >

Meet the Author

Laura McIntyre

Suggested next

24.05.2022 | Article

Respiratory tracker: Can you put a price on asthma care? UK HCPs discuss all on World Asthma Day

Bringing you the latest insights into online HCPs' respiratory disease related conversation

By Mark Sullivan

02.07.2022 | Article

Product Launch Tracker: HCPs celebrate 5th agnostic approval in Cancer alongside other approvals

with notable excitement being found for the FDA’s approval of Novartis’ 5th agnostic...

By Paul Cranston and Tomi Shobande

View all articles >